HC Wainwright Issues Positive Forecast for Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Price

Amylyx Pharmaceuticals (NASDAQ:AMLX) had its target price lifted by HC Wainwright from $28.00 to $34.00 in a report released on Wednesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Several other equities research analysts have also recently issued reports on the stock. Wall Street Zen cut shares of Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, December 20th. Bank of America lifted their price target on shares of Amylyx Pharmaceuticals from $15.00 to $19.00 and gave the company a “buy” rating in a report on Friday, February 20th. Stifel Nicolaus started coverage on shares of Amylyx Pharmaceuticals in a report on Tuesday. They set a “buy” rating and a $21.00 price objective for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a report on Monday, December 29th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Amylyx Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $19.56.

Amylyx Pharmaceuticals Stock Performance

Shares of Amylyx Pharmaceuticals stock opened at $15.05 on Wednesday. Amylyx Pharmaceuticals has a fifty-two week low of $3.00 and a fifty-two week high of $17.49. The company has a market capitalization of $1.65 billion, a P/E ratio of -9.71 and a beta of -0.31. The company has a fifty day moving average of $13.88 and a 200 day moving average of $13.17.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.01. Analysts forecast that Amylyx Pharmaceuticals will post -2.2 EPS for the current year.

Insider Buying and Selling

In related news, CEO Joshua B. Cohen sold 136,193 shares of Amylyx Pharmaceuticals stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $13.59, for a total value of $1,850,862.87. Following the completion of the transaction, the chief executive officer owned 3,378,621 shares in the company, valued at approximately $45,915,459.39. This trade represents a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Justin B. Klee sold 1,995 shares of the firm’s stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $13.89, for a total value of $27,710.55. Following the completion of the sale, the chief executive officer directly owned 3,379,398 shares of the company’s stock, valued at $46,939,838.22. The trade was a 0.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 151,203 shares of company stock worth $2,028,385. Insiders own 12.30% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Meeder Asset Management Inc. bought a new stake in shares of Amylyx Pharmaceuticals in the 4th quarter worth about $25,000. California State Teachers Retirement System bought a new stake in Amylyx Pharmaceuticals in the second quarter worth about $28,000. Ameritas Investment Partners Inc. purchased a new position in shares of Amylyx Pharmaceuticals during the second quarter valued at approximately $45,000. Caitong International Asset Management Co. Ltd grew its stake in shares of Amylyx Pharmaceuticals by 954.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,859 shares of the company’s stock valued at $47,000 after buying an additional 3,493 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in shares of Amylyx Pharmaceuticals by 433.2% in the second quarter. BNP Paribas Financial Markets now owns 7,267 shares of the company’s stock worth $47,000 after buying an additional 5,904 shares during the period. Institutional investors own 95.84% of the company’s stock.

Amylyx Pharmaceuticals News Summary

Here are the key news stories impacting Amylyx Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised its price target to $34 and maintained a buy rating, representing meaningful upside vs. the current price and signalling increased analyst confidence. HC Wainwright raises price target to $34
• Positive Sentiment: Stifel Nicolaus initiated coverage with a “buy” rating and a $21 price target, adding another institutional positive viewpoint on the stock. Stifel starts coverage, $21 PT
• Positive Sentiment: Q4 2025 results slightly beat estimates (EPS -$0.30 vs. consensus -$0.31) and management provided financials/updates in the earnings release — small fundamental beat that supports sentiment. Amylyx Q4 2025 press release
• Positive Sentiment: Company and analysts are refocusing investment thesis on avexitide (GLP‑1 receptor antagonist) with Phase 3 LUCIDITY topline expected in Q3 2026; Amylyx also reports a strong cash position (~$317M) projected to fund operations into 2028 — supports runway to key value‑creating milestones. Amylyx: LUCIDITY Trial Sets Stage For Q3 Inflection Point
• Neutral Sentiment: Market commentary and valuation pieces are re‑examining Amylyx after reduced losses and late‑stage pipeline progress; useful for framing risk/reward but not an immediate catalyst. A Look At Amylyx Valuation
• Neutral Sentiment: Reported short‑interest data for early March appears inconsistent (shows zero shares / NaN changes); there’s no clear evidence of a meaningful short squeeze or buildup based on the provided figures.
• Negative Sentiment: Analyst downgrade from “Strong Buy” to “Buy” and the discontinuation of AMX0035 for PSP reduce optionality from that program — this narrows the pipeline and was cited as the reason for the softer rating. Amylyx: LUCIDITY Trial Sets Stage For Q3 Inflection Point

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.